The secondary objectives of this study are:~To show that ILC2 levels differ between asthma patients with a TH2 (helper T cell type 2) profile and asthma patients with a non-TH2 profile. A TH2 profile is defined as (for a given patient):~circulating eosinophils > 500 mm^3 at least once during the year AND~positive allergy skin or specific IgE (Immunoglobulin E) test AND~induced sputum eosinophil level >3% of leukocytes AND~exhaled nitric oxide > 25 ppb.~To study the variation in ILC2 levels over time among asthma patients who obtained a good level of control compared to other patients. A good level of control is defined as:~no exacerbations during 6 months of followup (an exacerbation is defined as the un-planned need for care that modifies the patient's prescription for >48h)~FEV1 (forced expiratory volume in 1 second) value current / FEV1 best value > 0.8~symptom levels correspond to an ACQ (Asthma Control Questionnaire) questionnaire score of < 0.75 over the last 7 days
The primary objective of this study is to demonstrate differences in ILC2 blood levels between asthma patients and control patients.